Enz A - Search Results

1

Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.

Enz A, Boddeke H, Gray J, Spiegel R. Enz A, et al. Ann N Y Acad Sci. 1991;640:272-5. doi: 10.1111/j.1749-6632.1991.tb00232.x. Ann N Y Acad Sci. 1991. PMID: 1776750 Clinical Trial. No abstract available.

2

Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.

Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Enz A, et al. Prog Brain Res. 1993;98:431-8. doi: 10.1016/s0079-6123(08)62429-2. Prog Brain Res. 1993. PMID: 8248533 Review.

., 1992), no prohibitive peripheral side effects were seen, confirming in humans the results obtained in experimental animals (Enz et al., 1991). A multicentre clinical investigation in AD patients has been performed in Europe and is currently being evaluated....

., 1992), no prohibitive peripheral side effects were seen, confirming in humans the results obtained in experimental animals (Enz et …

3

SDZ ENS 163 a novel pilocarpine like drug: pharmacological in vitro and in vivo profile.

Enz A, Boddeke H, Sauter A, Rudin M, Shapiro G. Enz A, et al. Life Sci. 1993;52(5-6):513-20. doi: 10.1016/0024-3205(93)90309-q. Life Sci. 1993. PMID: 8382766

4

SDZ ENS 163 is a selective M1 agonist and induces release of acetylcholine.

Enz A, Shapiro G, Supavilai P, Boddeke HW. Enz A, et al. Naunyn Schmiedebergs Arch Pharmacol. 1992 Mar;345(3):282-7. doi: 10.1007/BF00168688. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1620233

5

M1 muscarinic receptors mediate intracellular calcium release in NB-OK1 human neuroblastoma cells.

Boddeke HW, Buttini M, Lichtsteiner M, Enz A. Boddeke HW, et al. Among authors: enz a. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):255-61. doi: 10.1007/BF00173537. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1407011

6

Muscarinic agonists for senile dementia: past experience and future trends.

Gray JA, Enz A, Spiegel R. Gray JA, et al. Among authors: enz a. Trends Pharmacol Sci. 1989 Dec;Suppl:85-8. Trends Pharmacol Sci. 1989. PMID: 2694530 Review.

7

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.

Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Giacobini E, et al. Among authors: enz a. J Neural Transm (Vienna). 2002 Jul;109(7-8):1053-65. doi: 10.1007/s007020200089. J Neural Transm (Vienna). 2002. PMID: 12111443 Clinical Trial.

8

Cyclosporins. Structure-activity relationships.

Fliri H, Baumann G, Enz A, Kallen J, Luyten M, Mikol V, Movva R, Quesniaux V, Schreier M, Walkinshaw M, et al. Fliri H, et al. Among authors: enz a. Ann N Y Acad Sci. 1993 Nov 30;696:47-53. Ann N Y Acad Sci. 1993. PMID: 8109856 Review.

9

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, Hourani J, Zolnouni P. Cutler NR, et al. Among authors: enz a. Acta Neurol Scand. 1998 Apr;97(4):244-50. doi: 10.1111/j.1600-0404.1998.tb00645.x. Acta Neurol Scand. 1998. PMID: 9576639 Clinical Trial.

10

SDZ ENS 163, a selective muscarinic M1 receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices.

Boddeke EW, Enz A, Shapiro G. Boddeke EW, et al. Among authors: enz a. Eur J Pharmacol. 1992 Nov 3;222(1):21-5. doi: 10.1016/0014-2999(92)90457-f. Eur J Pharmacol. 1992. PMID: 1468496

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101 results

Search Page